Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy

Kaname Miyashita, Kei Fujii, Yu Yamada, Hiroyoshi Hattori, Kenichi Taguchi, Takeharu Yamanaka, Mitsuaki A. Yoshida, Jun Okamura, Shinya Oda, Koichiro Muta, Hajime Nawata, Ryoichi Takayanagi, Naokuni Uike

研究成果: ジャーナルへの寄稿学術誌査読

12 被引用数 (Scopus)


Microsatellite instability (MSI) in haematopoietic malignancies has been controversial. Particularly in non-Hodgkin lymphoma, the data published to date lack unity. Using a unique fluorescent technique, we found MSI in eight (14%) tumours in a panel of 59 carefully selected non-Hodgkin lymphoma patients. Our fluorescent technique also reveals two qualitatively distinct modes of MSI, i.e. Type A and Type B. Based on our previous studies using DNA mismatch repair (MMR) gene-knock out animals, we have concluded that Type A MSI is a direct consequence of defective MMR. MSI observed in non-Hodgkin lymphomas was uniformly Type A, which implies that MMR deficiency occurs in this malignancy. Intriguingly, in non-Hodgkin lymphoma patients treated by CHOP/VEPA-based therapies, response to chemotherapy was significantly worse in those with microsatellite-unstable tumours (p = 0.027). As a consequence, the patient outcomes at 1 year after treatment were significantly less favourable in this population (p = 0.046), although the survival difference was not statistically confirmed in a longer term. These findings suggest that in some non-Hodgkin lymphomas MMR deficiency may lead to drug resistance in tumour cells and, consequently, to poor patient outcomes. In non-Hodgkin lymphoma, MSI may be a potential biomarker that predicts the tumour response against chemotherapy.

ジャーナルLeukemia Research
出版ステータス出版済み - 8月 2008

!!!All Science Journal Classification (ASJC) codes

  • 血液学
  • 腫瘍学
  • 癌研究


「Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。